AVCT — Avacta Share News
0.000.00%
Last trade - 00:00- £344.07m
- £344.92m
- £0.11m
Clinical data on AVA6000 in salivary gland cancers
Posting of Annual Report and Notice of AGM
Board Director Changes
Brief: Avacta Therapeutics Reports Group Revenues Of £6.31 Million For Year Ended December 31, 2025
Brief: Avacta Group Continues To Explores Multiple Commercial Opportunities with Strategic Partners
Notice of Preliminary Results and Presentation
Issue of Equity and Total Voting Rights
Pre|CISION® payload release vs approved ADCs
Avacta data AACR underline AVA6103 profile
Christina Coughlin - In Vivo 2026 Rising Leader
Q1 2026 Business Update
Avacta Announces Science Day 2026
First patient treated in Phase 1 trial of AVA6103
Brief: Avacta Therapeutics Says Placing & Subscription Represent 3.60% Of Issued Share Capital
Result of Oversubscribed Fundraise
Brief: Avacta Therapeutics Proposed Placing Via Accelerated Bookbuild & Subscription To Raise About £10 Million
Issue of Equity
Presentations of pre|CISION® Platform Candidates
Brief: Avacta Group Announces Phase 1 Study Opening For AVA6103